Literature DB >> 17922093

Prognostic significance of gastrin expression in patients undergoing R0 gastrectomy for adenocarcinoma.

Michael R Stephens1, Andrew N Hopper, Wyn G Lewis, Guy Blackshaw, Paul Edwards, Becky Osborne, Ian W Thompson.   

Abstract

BACKGROUND: Gastrointestinal (GI) hormones regulate several GI functions, including the proliferation and repair of normal mucosa, and hormone receptors may therefore be implicated in the growth, invasion, and metastasis of cancers of the GI tract. The aim of this study was to determine the cellular distribution of gastrin in intestinal-type gastric cancers, and to determine its relationship to outcomes after R0 gastrectomy.
METHODS: Eighty-six consecutive patients undergoing R0 gastrectomy for adenocarcinoma were studied. Normal gastric mucosa and tumor were stained for gastrin and their specific cellular distribution was determined.
RESULTS: The duration of survival of patients whose tumors exhibited well-differentiated gastrin-positive tumor (GPT) cells (n = 12) was significantly poorer than that of patients whose tumors were GPT-negative (5-year survival, 30% vs 54%; P = 0.037). Patients with GPT-positive intestinal-type gastric cancer (5 of 47 patients) had the poorest survival of all (median, 14 months; 5-year survival, 0%; P = 0.006). In a multivariate analysis, only lymph node metastases (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.2 to 3.79; P = 0.01) and the presence of GPT cells (HR, 6.61; 95% CI, 1.74 to 25.09; P = 0.01) were independently and significantly associated with durations of survival in patients with intestinal-type gastric cancer.
CONCLUSION: The presence of GPT cells in patients with gastric adenocarcinoma is a significant and independent prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922093     DOI: 10.1007/s10120-007-0429-4

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  23 in total

1.  One-year survey of carcinoma of the oesophagus and stomach in Wales.

Authors:  J K Pye; M K Crumplin; J Charles; R Kerwat; M E Foster; A Biffin
Journal:  Br J Surg       Date:  2001-02       Impact factor: 6.939

2.  Gastrin and colorectal cancer. Evidence against an association.

Authors:  R Yapp; I M Modlin; R R Kumar; H J Binder; R Dubrow
Journal:  Dig Dis Sci       Date:  1992-04       Impact factor: 3.199

3.  Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis.

Authors:  S A Watson; A M Smith
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

4.  Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.

Authors:  Guido Rindi; Roberto Fiocca; Anna Morocutti; Adam Jacobs; Neil Miller; Bjarni Thjodleifsson
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-05       Impact factor: 2.566

5.  Bombesin-mediated AP-1 activation in a human gastric cancer (SIIA).

Authors:  H J Kim; B M Evers; Y Guo; N A Banker; M R Hellmich; C M Townsend
Journal:  Surgery       Date:  1996-08       Impact factor: 3.982

6.  Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection.

Authors:  I D Penman; E el-Omar; J E Ardill; J R McGregor; D J Galloway; P J O'Dwyer; K E McColl
Journal:  Gastroenterology       Date:  1994-05       Impact factor: 22.682

7.  Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome.

Authors:  S J Panter; H O'Flanagan; M G Bramble; A P S Hungin
Journal:  Aliment Pharmacol Ther       Date:  2004-05-01       Impact factor: 8.171

8.  Postprandial hypergastrinaemia in patients with colorectal cancer.

Authors:  K Wong; K Beardshall; C M Waters; J Calam; G J Poston
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

9.  Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy.

Authors:  M G Bramble; Z Suvakovic; A P Hungin
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

10.  Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma.

Authors:  P Edwards; G R J C Blackshaw; W G Lewis; J D Barry; M C Allison; D R B Jones
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

View more
  6 in total

1.  The effect of continuous jejunal interposition on gastrointestinal hormones after distal gastrectomy.

Authors:  Zhen-Ye Lv; Zai-Yuan Ye; Qin-Shu Shao; Wei Zhang; Qin Zhang; Yuan-Shui Sun; Shu-Guang Li; Yuan-Yu Wang; Ji Xu
Journal:  Bosn J Basic Med Sci       Date:  2012-02       Impact factor: 3.363

2.  Human gastrin mRNA expression up-regulated by Helicobacter pylori CagA through MEK/ERK and JAK2-signaling pathways in gastric cancer cells.

Authors:  Jianjiang Zhou; Yuan Xie; Yan Zhao; Shu Wang; Yu Li
Journal:  Gastric Cancer       Date:  2011-04-22       Impact factor: 7.370

Review 3.  Importance of gastrin in the pathogenesis and treatment of gastric tumors.

Authors:  Michael D Burkitt; Andrea Varro; D Mark Pritchard
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 4.  Hypergastrinemia.

Authors:  Sunil Dacha; Mohammed Razvi; Julia Massaad; Qiang Cai; Mohammad Wehbi
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-02-18

5.  Chromosomal breaks at FRA18C: association with reduced DOK6 expression, altered oncogenic signaling and increased gastric cancer survival.

Authors:  Siew Hong Leong; Kyaw Myo Lwin; Sze Sing Lee; Wai Har Ng; Kia Min Ng; Soo Yong Tan; Bee Ling Ng; Nigel P Carter; Carol Tang; Oi Lian Kon
Journal:  NPJ Precis Oncol       Date:  2017-05-01

6.  LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis.

Authors:  Hironobu Shigaki; Yoshifumi Baba; Masayuki Watanabe; Asuka Murata; Shiro Iwagami; Keisuke Miyake; Takatsugu Ishimoto; Masaaki Iwatsuki; Hideo Baba
Journal:  Gastric Cancer       Date:  2012-11-21       Impact factor: 7.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.